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Abstract: This theoretical study seeks to critically review the use of excipients in the paediatric
population. This study is based on the rules and recommendations of European and American drug
regulatory agencies. On the one hand, this review describes the most frequent excipients used in
paediatric medicine formulations, identifying the compounds that scientific literature has marked
as potentially harmful regarding the side effects generated after exposure. On the other hand, this
review also highlights the importance of carrying out safety -checks on the excipients, which, in
most cases, are linked to toxicity studies. An excipient in the compilation of paediatric population
databases is expected to target safety and toxicity, as in the STEP database. Finally, a promising
pharmaceutical form for child population, ODT (Orally Disintegrating Tablets), will be studied.
Keywords: excipients; paediatrics; security; toxicology; STEP and ODT
1. Introduction
The scientific literature suggests that most commercialized drugs are not suitable to be
used on the paediatric population, as they are presented in an inappropriate pharmaceutical
dosage or form, or because of the excipients they contain. In the face of this reality,
compounding is the alternative for paediatric patients. Auxiliary substances or excipients
should be used in the development of a compounding formula in order to allow the drug
to be administered in an easily and personalized manner. By doing so, the active ingredient
will be formulated in a stable, effective, and safe form [1].
The process of formulating excipients in paediatrics is a complicated task that requires
various considerations to be accounted for in order to for them to be appropriate; variables
such as an acceptable taste, age, dosage forms, among others, must be taken into account
when selecting safe excipients. Furthermore, children’s rapid growth and development
are associated with changes in various organs, body composition, protein bonds, active
transport mechanisms and metabolic pathways, which must also be taken into account [2].
In addition to being a complicated task, it is also a critical step in the development of
paediatric formulations, as some acceptable excipients in formulations for adult patients
are not suitable for paediatric use.
It is thus of particular relevance to carry out an assessment of the safety of excipients
prior to their use in paediatrics. Indeed, Georg Schmitt [3] advocates for non-clinical safety
studies being carried out in juvenile animals to assess excipient toxicity or sensibility and
also to establish safe exposures in paediatric age groups. He specifically recommends
that excipient toxicity studies also be carried out, as they provide a detailed assessment
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of clinical risk. He further suggests that even excipients with significant toxic potential
for children may be acceptable after a rigorous assessment of the risk they pose is made.
Another factor to be considered for toxicological studies is the extent to which the target
disease may be alleviated by the formulation of that medicine. Thus, pharmaceutical
companies should filter the demands for safety assessments by selecting those that will
contribute to a potential therapeutic benefit, while helping to develop a reference list of
excipients generally considered safe for use in paediatric formulations. In this way, the
clinical decision-making process will be made easier.
This theoretical study’s main objective is to critically review the use of excipients in
paediatrics with an emphasis on the issue of safety, mainly on the basis of toxicological
studies. This will enable information to be obtained that will allow decisions to be made
regarding the masterful preparation of formulations. This study also seeks to investigate
the development of databases and initiatives in order to record corroborated information
on excipients for paediatric use, thus serving as a guide for clinical professionals.
To do this, databases such as Web of Science, PubMed, SciFinder and SciFindern
Search, as well as books related to the subject, were consulted. Please note that most of the
selected literature is from the last two decades. Subsequently, six tables were created to
provide details on the data obtained:
• Table 1. Toxicity database.
• Table A1. Most important characteristics of the excipients discussed in this review (in
alphabetical order).
• Table A2. Examples of solid and semi-solid medicines used in Spain for the paediatric
population: List of excipients and relevant characteristics of the pharmaceutical form
(PF) (performed consultation of CIMA database, September 2020).
• Table A3. Examples of liquid medicines used in paediatrics: List of excipients and
relevant characteristics of (PF).
• Table A4. Examples of FDA-registered drugs used in paediatrics (FDA database and
DAILYMED October 2020).
• Table A5. Examples of liquid formulations for paediatric use in research articles.





(accessed on 15 November 2020)
US Environmental Protection Agency’s
(EPA) National Center for Computational
Toxicology (NCCT)
STEP—Safety and Toxicity of Excipients
for Paediatrics *
www.eupfi.org/step-database-info/
(accessed on 15 November 2020)
European Paediatric Formulation
Initiative
TOXNET—Toxicology Data Network www.nlm.nih.gov/toxnet/index.html(accessed on 15 November 2020)
Specialized Information Services (SIS)
USA
Vitic www.lhasalimited.org/products/vitic.htm (accessed on 2 November 2020) Lhasa Limited
* The purposes of the STEP database can be consulted in the Appendix A.
2. Paediatric Regulatory Context
Changes in physical, metabolic and psychological processes that occur during chil-
dren’s growth, from birth to adulthood, suggest that children should not be considered as
young adults, and nor should they be grouped as a single group. Rather, the pharmaceuti-
cal development of paediatric drugs should focus on several acceptable dosage forms that
are able to meet the needs of most children in different age groups. This can be achieved by
developing dosage forms which facilitate the administration of a dose range which would
vary according to the child’s age and/or other important parameters [4].
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Before there were regulations for the development of paediatric drugs, children were
known as “therapeutic orphans”. They lost the advances of conventional medicine, since
the vast majority of advances were aimed at the adult population, and there were not many
approved medicines for children. Children were treated with approved drugs following
successful studies on adults, but with few or no trials on the paediatric population (off-label
use). The large number of subsequent issues with clinical trials on children, as well as
the need for drug authorization in the paediatric population, among other reasons, were
the driving factors for the creation of a legislative and regulatory framework for clinical
studies in paediatrics. The US pioneered these in the late 1980s, and with the adoption of
these paediatric regulatory initiatives, significant improvements were made [4].
It was only in 1997 that European regulators agreed to strengthen legislation on the
use of new medicines in children. In 2000, European health ministers asked the European
Commission to make proposals for a legislation to ensure that new paediatric medicines
placed on the market were tailored to the specific needs of children. In 2004, after a
major debate, a regulatory bill was issued, which took into account lessons learned from
paediatric regulation that the US was already addressing [5]. On 26 January 2007, the
Paediatric Regulation entered into force in the European Union, and focused mainly on
regulating the development of paediatric formulations for children between 0 and 18 years
of age, but also sought to:
• Ensure that these medicines were of good quality.
• Verify that paediatric medicines were produced following ethical and legitimate
research, that children were not subjected to unnecessary trials.
• Improve the accessibility and availability of information on drug use in the paediatric
population.
• Such regulations led to the establishment of the Paediatric Committee (PDCO), whose
main function was to regulate the studies that companies should conduct in children
as part of a Paediatric Research Plan (PRP) [6].
• The Paediatric Regulation consists of [7]:
• Regulation (EC) 1901/2006 of the European Parliament and of the Council on medici-
nal products for paediatric use; and
• Regulation (EC) 1902/2006, an amending regulation in which changes were made
to the original text in relation to the European Commission’s decision-making proce-
dures.
In October 2017, the European Commission published a ten-year report on the imple-
mentation of the Paediatric Regulation. The report showed an increase in medicines for
children in most therapeutic areas over the past ten years, especially in rheumatology and
infectious diseases. However, in rare diseases, progression was lower. A report on the first
five years was also published in June 2013, which concluded that paediatric development
had become a more integral part of the overall development of medicines in the European
Union [4,8].
The European Guideline on pharmaceutical development of medicines for paediatric
used [4] offers several tips for paediatric drug formulation.
Excipients in a paediatric formulation should be chosen appropriately, avoiding any
excipients that are potentially toxic or unsuitable for children. Choosing the right excipients
in the development of a new paediatric drug is one of the most important aspects, as it
requires special safety considerations. In general, the following aspects should be taken
into account when selecting an appropriate excipient for a paediatric medicinal product [4]:
• Excipient function in formulation and possible alternatives.
• Safety profile of the excipient for children in target age groups, based on a unique and
daily exposure.
• Expected duration of treatment: short term (a single dose for a few days) or long term
(weeks and/or months).
• Severity of the condition to be treated and therapeutic alternatives.
• Patient acceptability, including palatability.
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• Allergies and sensitization. Children suffer from sensitization problems more com-
monly than adults. Applicants should avoid, when possible, excipients with known
potential to cause sensitization or allergies.
If the use of any excipient in the formulation that produces or may pose any risk to the
child cannot be avoided, the added value of the chosen pharmaceutical form of dosing (and
the route of administration) should be balanced with the possible use of another. However,
security issues can only become apparent when the product is used on a larger scale.
Furthermore, the first joint paediatric regulatory action was taken by the ICH (The
International Council for Harmonization of Technical Requirements for Pharmaceuticals
for Human Use), an organization working on harmonizing drug regulation requirements
between the EU, Japan and the US. In July 2000 Guideline E11 (R1) was published: Clinical
investigation of medicinal products in the paediatric population, with the final version in
August 2017 [9].
The objectives of this guide were to encourage and facilitate the development of
paediatric medicines at the international level, as well as to provide a summary of critical
problems in the development of these medicines and new approaches to their safe, efficient
and ethical clinical study. ICH E11 became an important tool in the design of paediatric
clinical research worldwide, providing guidelines (rather than proscribing practice) [9,10].
The WHO launched the initiative Making Medicines Child Size in 2008 to issue a list of
essential medicines for children, betting on quality paediatric development and adequate
access of these medicines to the entire paediatric population, in particular underdeveloped
countries [11]. The most current one is the 7th edition, which was published in 2019 (WHO
model list of essential medicines for children) [12].
In the early 1980s, the FDA (Food and Drug Administration) began taking steps to
provide incentives to the pharmaceutical industry for the development of paediatric drugs.
In 1994, the Paediatric Labelling Rule was issued, requiring the authorization of a new
paediatric drug to be supported by safety and efficacy data to support its use. However,
that rule was not mandatory and was unsuccessful. For this reason, the US-FDA proposed
in 1998 Paediatric rule which proposed to guarantee the above-mentioned objectives, both
at and after the approval of the new drug [13].
It should also be noted that the FDA (Nonclinical Studies for the Safety Evaluation of
Pharmaceutical Excipients) published a document that provides guidance on the devel-
opment of safety profiles to support the use of new excipients as components of drugs or
biological products, which could be applied in paediatric experiments [14,15].
Examples of Databases and Initiatives for the Registration of Information on Excipients Used in the
Paediatric Population
It is certainly necessary to take into account the safety of excipients used in paediatric
products, as the toxicity of these excipients may differ from that of adults [16]. Under
this assumption, it is essential to develop methodologies that provide an integrated as-
sessment of exposure to potentially toxic excipients contained in medicines. Therefore,
in 2007, members of pharmaceutical industries, hospitals and academics interested in
improving drug formulations in paediatrics founded the European Paediatric Formulation
Initiative (EUPFI). The latter sought to address safety problems linked to excipients used
in children [17], as well as the development of platforms for the systematic evaluation of
excipients in new-borns [18].
EuPFI is currently a consortium of 10 pharmaceutical companies, 5 universities, 1
hospital and, exclusively, the European Medicines Agency (EMA) as an observer. The goals
and objectives of this consortium are summarized in [19]:
1. Identify the problems and challenges associated with the development of paediatric
formulation and consider ways to obtain better medicines and dosage forms clinically
relevant to children.
2. Promote early pharmaceutical consideration for the development of paediatric medicines.
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3. Identify potential information and knowledge gaps in the development of paediatric
formulations.
4. Improve the availability of information from paediatric formulations.
The scientific literature shows that excipients commonly used in adult medicines
have been associated with high toxicological risks and safety problems in children [20].
Following the United States Paediatric Formulation Initiative (USPFI) and Global Paediatric
Research (GRIP), the Paediatric Excipient Safety and Toxicity Database (STEP) was created
to address the need for effortless access to information about the excipients’ safety and
toxicity [21]. The STEP database is presented as a resource of information to facilitate
access to data on the use and acceptability of excipients in children, thus allowing a rapid
evaluation of the risks due to the use of certain excipients in the paediatric population and
an improvement in the scientific decision making [2,22]. Furthermore, the STEP database
provides comprehensive and comparative information on the safe use and acceptability of
excipients in paediatrics. For the reasons listed above, the STEP database stands out with
respect to other existing public resources (such as TOXNET) or databases (such as Vitic or
ACToR) that organize their informational content in free text format, thus preventing data
from being filtered as needed (see Table 1) [23].
In general, the above purposes go in line with increasing the number of excipients
registered in the database to be useful in practical research. Therefore, the following
selection criteria were considered for excipients of interest [2]:
1. Excipients known to be toxic/have general safety issues.
2. Frequency of appearance as contaminants or toxics in paediatrics (where applicable).
3. Evidence in the toxicity literature in paediatrics. The above criteria were applied
to identify excipients for inclusion in the STEP database. Excipients were short-
listed/prioritized through surveys within EU and US PFI members.
According to the above criteria, in the development of databases on the safety and
toxicity of excipients in the paediatric population, the following are prioritized, as they are
most likely to cause damage and side effects in this population [2]:










In 2014, the first version of the STEP database was launched for the systematic evalua-
tion of its integrity, quality, configurability, usability, and maintainability under the daily
practices of the different and diverse professionals who use it. After launch, a validation
study of the tool was initiated with the following objectives [2]:
1. Validate the STEP Version 1 database against the potential needs of end users to
ensure that the STEP database meets users’ expectations.
2. Evaluate the functionality and usability of data application by
a. Ensuring proper ease of use (navigation), understanding and user satisfaction.
b. Characterizing how easy it is to perform a task using the database.
c. Identifying problems in interaction with systems.
3. Evaluate the impact of this database on the development of paediatric medicines.
4. Establish viable recommendations to further improve the functionality of the system
and increase its beneficial effects on the development of paediatric medicines.
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The results of the validation study identified different database usage issues, which
are grouped into three areas: I. Content and presentation of results; II. Adequacy of the
database to the characteristics of different users, navigation features; and III. Search. Many
of the problems observed might have happened due to assuming that users would have
sufficient knowledge, therefore some elements were not clearly exposed for the new user to
understand. Furthermore, users with limited computer skills may also find the registration
process confusing. These issues involved changes and improvements to STEP design and
functionality, making it a more efficient database when deriving from a Version 2 [21].
To perform an adequate risk/benefit assessment of the current medication standard,
it is necessary to compare the daily amount of excipients in the most vulnerable patient
with clinically established safety levels for the same age group. The SEEN project is
an example of this, as it developed a retrospective cohort study, with neonatal patients
(age 5 or younger) treated with multiple medicines. Preparations were recorded with
ethanol, propylene glycol, benzyl alcohol, parabens, aspartame, glycerol, sorbitol and
polysorbate-80 and cumulative amounts [24] were calculated.
The results obtained demonstrated limited knowledge about the acceptability of
different dosage forms, flavours and, more importantly, the safety of formulation excipients
in relation to the age and stage of development of children [24].
3. Excipients: Functions and Main Adverse Effects
Paediatric formulations need excipients to maintain their quality and promote the
acceptability of childhood patients [25]. However, just because they are necessary does not
mean that they are toxicity-free products; in fact, a study by Georgi and collaborators [26,27]
confirms that many of the medicines used in paediatrics contain some toxic or potentially
toxic excipient for the paediatric population, with this data being present in two-thirds
of new-borns in 21 European countries. Thus, excipients used in paediatric formulations
require a thorough assessment of short-term and long-term safety prior to their use in these
formulations [28]. A classification of the main excipients will then be developed according
to the role they play in the formulation, mentioning the possible adverse effects on the
paediatric population. Furthermore, a summary appendix (Appendix B (Table A1)) of the
excipients discussed in this paper will be prepared.
3.1. Diluents
Lactose, starch and microcrystalline cellulose are often used as diluents, as they are
generally safe in the adult population.
3.1.1. Lactose
Lactose, which is a mandatory excipient, is recommended not to be used in patients
with lactose intolerance and is contraindicated in patients with galactosemia [1]. It may
cause hypersensitivity reactions in children and new-borns. Infants with lactose intolerance
do not properly metabolize lactose, due to the deficiency of the enzyme lactase, thus causing
the accumulation of lactic acid, hydrogen and carbon dioxide. Symptoms such as severe
abdominal pain, flatulence, bloating or swelling and diarrhoea may, therefore, appear, as
well as systemic symptoms such as muscle, joint pain and eczema [28]. It should be noted
that children may sometimes have very severe and prolonged reactions to lactose that can
lead to additional complications, such as dehydration, bacterial proliferation and metabolic
acidosis [1,28].
Starch, dehydrated calcium hydrogen phosphate, erythritol and cellulose powder are
alternatives to lactose in paediatric formulations. They have lactose-like flow properties
and produce tablets that can disaggregate in a time less than lactose [28].
3.1.2. Starch
Starch is one of the most commonly used excipients and, in addition to being a diluent,
it has binder and disintegrating properties. Due to its properties, starch should be preserved
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in a dry environment, as it can be an excellent growing medium for microorganisms in
case of moisture, which may cause microbiological contaminations. In addition, it may
give proliferation of carcinogenic aflatoxins, if contaminated by two species of fungi closely
enhanced by each other: Aspergillus flavus and Aspergillus parasiticus [29].
3.1.3. Microcrystalline Cellulose
Microcrystalline cellulose is a partially depolymerized purified cellulose that is pre-
sented as a white, odourless and tasteless crystalline powder composed of porous particles.
It is commercially available in different particle sizes and moisture grades that have differ-
ent properties and applications. It is considered a relatively non-toxic and non-irritating
material. It is not absorbed systemically after oral administration and therefore has little
toxic potential [29,30].
Microcrystalline cellulose is used in pharmaceutical products, mainly as a binder and
thinner in tablet and oral capsule formulations. In addition to its use as a binder and
thinner, it also has some lubricating and disintegrating properties that make it useful for
forming tablets [30].
3.2. Solvents
Some of the most common solvents are water, ethyl alcohol, propylene glycol (PG),
glycerol and polyethylene glycol [28,29].
3.2.1. Water
Water is the most commonly used agent in paediatric formulations, as liquid prepara-
tions are easier to administrate and allow a more accurate dose adjustment [1,29]. Water is
an ideal medium for the proliferation of microorganisms (bacteria and fungi) despite their
purification, which is why antimicrobial agents have to be added.
In paediatric oral formulations, the total volume of fluid is of vital importance for the
taste and ability to adequately measure the volume to be administered: in children under
5 years of age a volume of less than 5 mL should be administered and, in children under
10 years of age, a volume of less than 10 mL [29] should be administered.
3.2.2. Ethyl Alcohol (Ethanol)
Ethanol is one of the excipients of concern to international health regulatory agencies,
as it causes neurotoxicity and cardiovascular problems in the paediatric population; it is a
potentially harmful excipient in neonates. For this reason, permissible maximum limits
have been set and, in some countries, non-alcoholic medicines are to be established. It is a
very permeable excipient with regard to the blood–brain barrier, and the one most com-
monly used in oral medicinal products, reaching 63% of cases [26]. It is rapidly absorbed
into the gastrointestinal tract and is primarily metabolized in the liver to acetaldehyde,
which is oxidized to acetate [29].
Indeed, Macrel and Bernando’s review of liquid formulations in Brazil has furthered
our understanding of the high use of ethanol. These researchers demonstrated that ethanol
is used in various concentrations and functions: as solvent (main function), co-saver,
flavouring agent, preservative and as an extraction solvent in herbal medicines [26,27]. It
also has antimicrobial properties and increases the permeability of many preparations [29].
The use of ethanol as an excipient carries potential hazards and adverse effects,
which are already observed at a dose of 100 mg/dL. These effects include hypoglycaemia,
acidosis and hydro-electrolytic alterations. Very high intake can lead to stupor, coma,
respiratory depression and cardiovascular collapse. Hypoglycaemic seizures may also
occur in children [29,31]. For all these side effects, any alcohol should be avoided in
paediatric forms. However, it is still used in many liquid preparations, because it is the
only solvent that allows the solubilization of certain active substances [29].
In both the United States and the European Union, guidance on maximum ethanol
limits in medicinal formulations is increasing [17]. According to the World Health Orga-
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nization and a regulation existing in the United States, the maximum alcohol content in
paediatric formulations should not exceed the limits specified in Table A1 [29,31,32].
It should be noted that ethanol was also able to interact with many active substances
of other medicines that the child is taking [29] and, therefore, possible interactions must
be studied prior to concomitant administration. Furthermore, new contributions in the
scientific literature on excipients, including ethanol, is expected to help health professionals
predict the risks of using a particular excipient, especially in the paediatric population. For
example, the guideline excipients in the label and package leaflet of medicinal products for
human use alerts on the risk of the use of ethanol and proposes changes on its use.
3.2.3. Propylene Glycol (PG)
PG is used as a solvent to stabilize substances that are not water soluble, in parenteral
and non-parenteral formulations. It also has moisturizing, antimicrobial properties and
can be used as plasticizer. It is rapidly absorbed through the gastrointestinal tract and
damaged skin and metabolized in the liver to lactic acid and pyruvic acid [29].
Exposure to high doses of PG may affect the Central Nervous System, especially in
new-borns and children under 4 years of age [29]. Due to children’s physiological and
metabolic immaturity, PG can accumulate rapidly causing toxicity [33]. In new-borns,
its half-life is very long, almost seventeen hours, compared to that of adults, which is
about five hours [29]. The GRAS (Generally Recognized as Safe) classification of excipients
typically does not consider the differences in physiological and metabolic maturation
between the paediatric and adult populations [33], a fact that justifies some important
adverse reactions presented by PG in the paediatric population [29]:
• Hyperosmolar syndrome in burnt children with topical arsenic sulfadiazine ointment
containing PG.
• Precipitation of irreversible deafness in pretermits who received a multivitamin com-
plex containing PG.
• Parenterally it is possible to observe haemolysis, seizures, respiratory depression,
hypertension.
• Contact dermatitis is topically observed.
In the 1980s, cases of biochemical abnormalities, including hyperosmolarity, lactic
acidosis and elevated levels of creatinine and bilirubin, were documented after exposure to
3 g/day of PG and for at least 5 consecutive days. Clinical symptoms, including seizures
and bradycardia episodes [33], then appeared. In 2011, the U.S. FDA reported health
problems in premature new-borns associated with the use of Kaletra® (lopinavir/ritonavir)
solution; liquid preparation containing high amounts of PG and ethanol [33,34].
Exposure to PG in new-borns and children under 4 years of age remains common,
despite historical and contemporary reports dealing with toxic adverse effects of this
excipient. Thus, the study of Allegaert J. [33] in terms of the PG research project in new-
borns is of great interest, as it provides scientific evidence on the tolerance and plasma
clearance of this excipient, including differences in elimination pathways (renal pathway
compared to the hepatic pathway).
3.2.4. Glycerol
Glycerol, a mandatory excipient (E-422), is used as solvent, sweetener, viscosizer and
preservative.
When used at high concentrations (more than 40%), it can cause mucositis in the
stomach, as well as diarrhoea and electrolyte disturbances due to its hygroscopic and
osmotic properties. Therefore, a maximum amount of 10 g/dose [1,29] has been established.
In the adult population glycerol has few adverse effects. However, cases of neurologi-
cal toxicity have been reported in the paediatric population [29].
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3.2.5. Polyethylene Glycol (PEG)
PEG is a polar and water-soluble substance used as a co-solvent, suspensor and
viscosity agent. The PEG 400 is the most used in liquid formulations. It may cause some
laxative effect when taken orally, with the maximum daily dose established in adults at
10 mg/kg/day [1].
PEG has low oral bioavailability and renal elimination. Due to its properties, sig-
nificant adverse effects such as diarrhoea and nephrotoxicity have been reported, so the
maximum recommended daily dose is 10 mg/kg body weight [1]. It can also cause some
laxative effect when taken orally. When new-borns and infants are exposed to high doses




Phthalates play a primary role as a coating agent (film-forming, plasticizer) in medici-
nal formulations.
Exposure of pregnant women to phthalates has been associated with abnormalities in
the development of the foetus, such as cleft palate and skeletal malformations; abnormali-
ties that can end in stillbirth. It was observed that they have a high potential to produce
toxicity in the development of experimental animals, as well as in their reproduction [28].
Due to these risks of certain phthalates to health, in March 2012, the CDER published
a guide to orient the pharmaceutical industry on the use of phthalates: “Limiting the use of
certain phthalates as excipients in CDER regulated products”. This guidance document
recommends limiting the use of certain phthalates, such as dibutyl phthalate (DBP) and
di(2-ethylhexyl) phthalate (DEHP) [28].
3.4. Preservatives
Preservatives are a group of excipients that prevent microbial growth and, conse-
quently, the degradation of the active substance and the possible alteration of the organolep-
tic characteristics of the final formula [35].
The American Academy of Paediatrics does not recommend the use of preservatives in
reparations for patients under 3 years of age due to the lack of physiological and metabolic
maturation of these patients. This lack of maturation may lead to the accumulation
of preservatives in the liver, a fact that increases the risk of cardiovascular collapse, in
addition to producing non-specific reactions or even allergies [1,35]. It should be noted
that preservatives are not contraindicated in children under 3 years of age, but should only
be used in imperative cases [1].
3.4.1. Sodium Benzoate
Sodium benzoate is a preservative widely used in pharmaceutical and cosmetic for-
mulations, at concentrations between 0.02% and 0.05% [29]. Its maximum activity occurs
in weakly acidic pH 4.5 solutions and is inactive at pH values greater than 5 [35].
As side effects, it can cause contact hives and other allergies. In premature children,
its use is contraindicated, as it presents a risk of metabolic acidosis and jaundice [29,35].
One of the large prospective studies conducted by Nellis and collaborators [36,37] in
hospitalized neonates in Europe described the administration of eight potentially harmful
excipients of interest (EOI) (parabens, polysorbate 80, propylene glycol, benzoates, sodium
saccharine, sorbitol, ethanol and benzalkonium chloride) and identified risk factors re-
sulting from exposure. Neonates appear to lack the ability to conjugate benzoates with
glycine, leading to the accumulation of benzoic acid that can cause metabolic acidosis and
neurotoxicity [26,27].
The ESNEE (European Study of Neonatal Exposure to Excipients) clinical study [38]
showed that sodium benzoate was found in 10 medicines given to new-borns, despite
being a highly toxic excipient to them. Preservatives such as parabens (and their sodium
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salts) and propyl para-hydroxy-benzoate were also found in 24 paediatric medications,
and ethanol in 8.
3.4.2. Benzyl Alcohol
Benzyl alcohol presents antibacterial properties. For that reason, it is used as a preser-
vative in a lot of medicines. Its activity depends on the pH; being at it is maximum at a low
pH (between 2.5–4.5). It is used at the concentration of 0.01–0.15% in oral preparations [35].
In adults, it is metabolized to benzoic acid, which is conjugated in the liver with
glycine. As a result, the acid hippuric formed is excreted in urine. However, in new-borns,
this conversion of the benzoic acid into hippuric acid is very diminished, because of the lack
of liver maturation. That justifies fatal intoxication cases in new-borns who had their um-
bilical catheters cleaned with benzoic acid. Consequently, cases of metabolic acidosis and
respiratory depression occurred. Additionally, other adverse effects have been described,
like intraventricular bleeding, cerebral palsy and developmental delay. In some cases, there
have been reactions of hypersensitivity, allergy and contact dermatitis [29,39–41].
In the 1990s, Svinning and collaborators [42] conducted a review of the medical records
of babies who weighed less than 1250 g at birth and were admitted to the neonatal intensive
care unit. The main objective of this study was to assess the impact of the toxicity of benzyl
alcohol, following discontinuation of the use of solutions to wash intravascular catheters
containing benzyl alcohol. A significant decrease in mortality rate and incidence of Grade
III/IV intraventricular haemorrhage was observed among infants weighing less than 1000 g
at birth who were not exposed to benzyl alcohol (as opposed to those who were).
The maximum dose of benzoic acid (and other benzoates, calculated as benzoic
acid) recommended by WHO is 5 mg/kg body weight per day in adults, a dose that, in
children, logically, should be much lower [29,35]. As the effects on new-borns are severely
toxic, the U.S. FDA has recommended the exclusion of benzyl alcohol from medications,
intravenous fluids, and heparin washing solutions for them [36]. The EMA states that
any medicine containing benzyl alcohol “should not be given to premature babies and
new-borns” [42,43]. In fact, currently, any exposure to benzyl alcohol is contraindicated in
children under 3 years of age [44].
3.4.3. Benzalkonium Chloride
Benzalkonium chloride is a quaternary ammonium used in ophthalmic preparations
at a concentration of 0.01–0.02% (v/v). Generally, it is non-irritating or sensitizing and is
well tolerated in skin solutions.
As a side effect, it can cause bronchoconstriction in asthmatic patients, if used in
nebulization solutions. Furthermore, cases of ototoxicity may occur in otic preparations,
hypersensitivity in topical skin preparations and respiratory failure in infants who ingest
this excipient, with this side effect being the most severe [29].
3.4.4. Thiomersal
Thiomersal is a preservative widely used in vaccines and topical preparations, such
as eye drops. Its toxicity is similar to mercury: in fact, it contains a mercury atom in
its molecular structure. The concentration used depends on the medicinal product: in
injectable preparations 0.01% is used and in ophthalmic solutions between 0.001% and
0.15% [30].
Several allergic hypersensitivity reactions (e.g., erythema, vesicles) have been reported.
Therefore, health authorities have recommended their withdrawal from vaccines at risk
of toxicity. Recently, thiomersal has also been implicated in the onset of autism spectrum
disorders in children who received aluminium salt vaccines as an adjuvant. Accordingly,
various countries (including Spain) no longer market paediatric vaccines with this compo-
nent [29]. The use of single-dose vials is recommended in many cases to prevent the use of
preservatives such as thiomersal or sulphites such as sodium metabisulphite [28].
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3.4.5. Parabens
Parabens are the most commonly used preservatives (also in cosmetics and foods),
due to their wide antimicrobial spectrum and their effectiveness over a very wide pH range
(between 4 and 8) [29,35].
Parabens are of mandatory declaration. They are used at concentrations between
0.01 and 0.2% [45], although it is most common to use a mixture in proportion 10:1 (0.2%
methylparaben + 0.02% propylparaben). The maximum recommended daily dose is
10 mg/kg body weight [35].
They may produce a cross-hypersensitivity reaction in patients allergic to aspirin. This
is because the main metabolite of parabens is hydroxyparabenzoic acid, structurally very
similar to aspirin [29].
Recent pharmacovigilance studies have highlighted certain questions about the pur-
ported safety (non-teratogenic or carcinogenic) of parabens [29]. Alternatives should
therefore be found, especially in paediatric formulations. Antimicrobials are not necessary
for parenteral formulations. The absence of parabens and benzoates in 85% of parenteral
prescriptions suggests that administration of these excipients can be largely avoided [36].
3.5. Antioxidants
Antioxidants are a group of chemical compounds used to prevent oxidation of the
active substances in formulations [29].
3.5.1. Sulphites
Sulphites are antioxidants widely used in different formulations; sodium sulphite,
sodium bisulfite, sodium metabisulphite and potassium metasulfite [29] are the most
common.
Regulatory agencies (e.g., FDA, EMA) consider excipient sulphites safe. However,
they present risks and possible fatal side effects derived of their use. One of the most
common cases occurs in asthmatic patients, who may develop severe bronchospasm if they
take medicines containing sulphites in their formulation [29].
The antioxidants constitute a group of compound chemists used to avoid the oxidation
of the active principles in the formulations [29].
It should be noted that a large number of people are sensitive to sulphites and may
experience a variety of symptoms, including dermatological, gastrointestinal and respi-
ratory symptoms. However, reactions that develop in the respiratory tract explain most
cases of sensitivity to sulphites. It is important to note that several individuals experience a
variety of symptoms after exposure to sulphites; therefore, skin, intestinal and respiratory
reactions can occur simultaneously and in various combinations and severity. People with
sensitive skin who regularly use cosmetics or topical medications containing sulphites
have chronic skin symptoms, especially on the hands, perineum and face. Sensitivity
to sulphites is a very real problem that significantly affects the health of many people,
especially asthmatics. Sensitivity to sulphites should be considered when people show
adverse reactions to a variety of exposures, without an obvious pattern, particularly when
those people experience worsening asthma symptoms after consumption of foods such as
dried fruits and wines, or adverse skin reactions, after the use of cosmetics or medicinal
creams [46].
3.5.2. Propyl Gallate
Propyl gallate is an antioxidant used to prevent the breakdown of fatty acids. It is
used at a concentration of 0.1% and also has a synergistic effect with other antioxidants. In
neonates it can cause dermatitis, skin allergy and methemoglobinemia [29].
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3.6. Sweeteners
The use of sweeteners varies between routes of administration and, like preserva-
tives, are not necessary in parenteral administrations [36,37]. They have been linked to
photosensitivity reactions, diarrhoea and poor absorption of nutrients [36,47].
The most commonly used sweeteners in pharmaceutical formulations are sucrose,
sorbitol, mannitol, aspartame and sucralose.
3.6.1. Sucrose
Sucrose is a natural disaccharide that is hydrolysed in the gut into two monosaccha-
rides: glucose and fructose.
In children with type I diabetes, the use of sucrose should be avoided. Very high
concentrations (up to 35% are used for liquid formulations such as syrups). When the
patient needs prolonged treatment with these preparations, he or she is at risk of dental
damage. It has also been described that administration at very high doses on a daily basis
may be carcinogenic [29].
3.6.2. Sorbitol
Sorbitol is a monosaccharide that is not absorbed into the digestive tract and is
therefore considered safe in paediatric patients, although it is laxative at high doses. It is
also used as a diluent as well as capsule plasticizer [29].
Sorbitol is another example of an excipient that causes gastrointestinal disorders, such
as abdominal pain, swelling, flatulence, vomiting and osmotic diarrhoea. Because sorbitol
is metabolized to fructose, it should be avoided on children with fructose intolerance and
hypoglycaemia. In isolated cases it can cause liver damage leading to coma and even
death [28–30].
In infants the accumulation of sorbitol can lead to diabetic complications such as
retinopathy and cataracts. Therefore, the amount of sorbitol is limited to 0.3 mg/kg in
paediatric formulations [28].
3.6.3. Mannitol
Mannitol is used as a sweetener and as a diluent. It has been linked to severe ana-
phylactic reactions in paediatrics [29]. As in the case of sorbitol, it is not absorbed into the
digestive tract, so it has laxative properties at high doses.
3.6.4. Aspartame
Aspartame is an artificial sweetener that has 180 and 200 times more sweetener power
than sucrose. Because of this, it is the most used sweetener in the pharmaceutical and food
industry. It is a disaccharide made of an aspartic acid and a methyl phenylalanine ester. It
is an excipient of mandatory declaration and its maximum dose has been set at 40 mg/kg
body weight [29,35].
Phenylalanine is very harmful for patients with phenylketonuria, as well as for preg-
nant mothers who carry a foetus of such metabolopathy. The use of aspartame in patients
with phenylketonuria should be avoided. The adverse effects of aspartame that have
been described are: neurological (neurotoxicity, epilepsy, headache, panic attack and hal-
lucinations), hypersensitivity reactions (vascular and granulomatous panniculitis) and
cross-reaction with sulphonamides [29].
3.6.5. Saccharine
Saccharine is also an artificial sweetener 300–600 times stronger that sucrose, but if
not used properly it can leave a residual bitter taste. Your daily dose should not exceed
2.5 mg/kg body weight. It is recommended to limit the daily dose in children and pregnant
women [29,48].
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Currently, controversy about its safety remains present, as in adults it has been linked
to bladder cancer when used at very high doses. Adverse effects of saccharine include
hives, itching, photosensibilization, eczema, as well as nausea and diarrhoea [29].
3.6.6. Sucralose
Sucralose has a sweetener power between 100 and 300 times higher than sucrose. Its
maximum daily dose is 15 mg/kg in weight.
Sucralose is a non-toxic compound and is also not irritating, but it is not considered
totally inert. It can increase the expression of cell flow transport protein glycoprotein P
and two cytochrome P450 isoforms, which are essential substances in the drug purification
process.
Furthermore, sucralose alters the composition of the microbiome of the digestive tract,
which ends up causing the reduction of the proportion of beneficial bacteria. In addition,
if cooked at high temperatures, chloropropanol can form, which is a toxic compound.




Polysorbates are partial esters of sorbitol fatty acids and their copolymerized anhy-
drous with ethylene oxide. They are used as dispersant agents, emulgents, non-ionic
sanitary surfactants, solubilizers, and moisturizers, among other things.
In general, they are considered non-toxic and non-irritating. However, they have
been associated with serious side effects, including deaths in under-weight neonates who
received vitamin E preparations with this substance [25]. In addition, polysorbate 80 has
been associated with increased mortality in new-borns [42].
3.8. Colorants
Colorants are excipients used to facilitate the identification of the formula by parents
and patients. The most commonly used dyes are whip dyes, quinolones, triphenylmethane
and xanthines.
Tartrazine (yellow number 5) has been implicated in anaphylactic reactions, edema,
asthma, bronchospasm, eosinophils, angioedema and hives in patients with sensitivity to
it. It appears to cause histamine degranulation of mast cells [29]. As a result, most global
regulatory agencies restrict the use of dyes such as tartrazine, because azo dyes have been
linked to hypersensitivity and ADHD reactions in children. These dyes can be replaced by
plant dyes such as annatto, malt beta-carotene and turmeric and should not be used at all
in paediatric formulations [28].
3.9. Excipients not Recommended in Paediatrics and Paediatric Formulations
To investigate the exposure of children to excipients not recommended at an early age,
a compilation of paediatric formulations (nationally and internationally) was made (see
Appendices C–F). As will be seen below, most of these formulations contain some excipient
not recommended in paediatrics:
In Appendix C, there is a summary table (Table A2) of examples of solid and semi-
solid medicines used in the paediatric population, marketed in Spain. Additionally, a
list of excipients and relevant characteristics of the pharmaceutical form (PF) is shown
(performed consultation of CIMA database, September 2020). It clearly shows that the
reason such excipients are not recommended for the paediatric population is because of
the adverse effects they may cause, which include:
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• Approximately 100% of the formulations shown here carry at least one excipient not
recommended for the paediatric population.
• Benzalkonium chloride, methyl para hydroxybenzoate and propyl para hydroxyben-
zoate are some of the most commonly used preservatives in solid and semi-solid
formulations for paediatric use, even though they are considered to be potentially
toxic in neonates.
• Sucrose, aspartame and mannitol are used as sweetener. 100% of the oral solid formu-
lations collected in Table A4 carry at least one excipient of these: 40% of formulations
carry mannitol and aspartame; 20% carry the 3 excipients; 20% sucrose and aspartame
and the remaining 20% only sucrose.
• Propylene glycol is another excipient commonly used in solid formulations as a
solvent, moisturizer and preservative. Caution should be exercised in children under
4 years of age and neonates, as propylene glycols, at high doses, may cause alterations
in the Central Nervous System, in addition to other side effects discussed in the
previous sections of this paper.
• Microcrystalline cellulose, methylcellulose and ethyl cellulose are one of the most
commonly used excipients in solid formulations. They have no major side effects, but
in high amounts they can cause a laxative effect.
• Most of the solid formulations collected in Table A2 use flavourings such as grape
essence, lemon flavouring, caramel cream aroma or orange essence, in order to achieve
a better palatability. The main drawback of their incorporation into paediatric formu-
lations is that they usually have a complex and poorly known composition [49].
• Lanolin is an excipient used in pastes and ointments, which are frequently used in the
paediatric population. This excipient may cause skin hypersensitivity reactions, which
is why caution should be exercised in patients with known sensitivity issues [50].
Appendix D (Table A3) lists marketed liquid formulations suitable for the paediatric
population. Liquid formulations are the most common in paediatrics because of their easy
administration. The need for at least one liquid formulation of any drug indicated in the
paediatric population is becoming increasingly noticeable. Not all active principles are
soluble or stable in water. Therefore, excipients are used in liquid formulations to improve
the solubility of certain active principles and/or increase their stability. The problem is that
most excipients found in adult formulations should not be used in paediatrics. However,
as shown in Table A3, there are a wide variety of marketed formulations indicated in
paediatrics that contain these non-recommended excipients:
• Ethanol, sorbitol and propylene glycol, despite being contraindicated in paediatrics,
especially ethanol, are still included in some paediatric formulations.
• The addition of non-recommended sweeteners, such as sucrose, sucralose or sodium
saccharine, is also seen in these paediatric formulations.
• The addition of preservatives in paediatric formulations should be avoided as much
as possible, and if necessary, in the least amount. Parabens are among the safest
preservatives in paediatrics, yet others that are not recommended are still used (e.g.,
Table A3: sodium benzoate, benzoic acid and benzyl alcohol). Benzalkonium chloride,
despite not being recommended for asthmatic patients, is used for the formulation of
most eye drops, nasal drops and gothic drops.
Appendix E (Table A4) and Appendix F (Table A5) provide examples of FDA-registered
drugs (liquids and solids) and liquid formulations in paediatric use research, respectively.
Like the other examples provided, these medicinal products and liquid formulations
contain at least one excipient not recommended for the paediatric population, such as
propylene glycol, polysorbates, methyl or propyl para hydroxybenzoate, benzyl alcohol,
benzoic acid, ethanol or sucralose, among others.
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• Excipients not recommended for paediatric population are most commonly used in
oral solutions and suspensions (referred to in Tables A4 and A5, propylene glycol,
benzoic acid, polyethylene glycol, polysorbate 80 and sodium benzoate).
• Like the other examples, there is also frequent use of sweeteners (fructose, sucrose,
sucralose, aspartame and sodium saccharine).
• Benzalkonium chloride is one of the most commonly used preservatives in ophthalmic
and nasal drops, as shown in Table A4. It is usually a safe excipient, but can cause
serious adverse effects, such as bronchoconstriction in asthmatic patients, ototoxicity
in erotic preparations or respiratory failure in infants who ingest this excipient, this
adverse effect being the most severe.
4. Promising Pharmaceutical Form in the Paediatric Population: ODT and 3D
Drug Printing
The development of Orally Disintegrating Tablets (ODT) has received greater interest
among researchers and the pharmaceutical industry over the past decade. ODT tablets are
designed to dissolve quickly upon contact with saliva, in the absence of additional water,
compared to traditional tablets [51].
ODT tablets offer several advantages, combining the properties of solid and liquid
formulations. They are quickly ingested when inserted into the tongue, eliminating the
need to chew the tablet, swallow it intact or take it with water. Currently, they are a
widely accepted form of dosing, especially for patients who have difficulty swallowing
(paediatric and geriatric), and for the treatment of patients where therapeutic compliance
is difficult [51,52].
As a result of the rapid disintegration of ODT tablets, the active substance comes into
contact with taste buds, so a key aspect to consider in these formulations is palatability. It
is necessary to mask the taste of bitter active ingredients in order to develop successful
formulations. In the past, sweeteners and aromas were used as methods of flavour masking
in dispersible or rapidly disaggregation tablets. However, these additives were not a
sufficient means to completely mask the taste. Currently, with scientific and technological
advances, different dosing alternatives are available to mask the taste, such as freeze-
deriding, microencapsulation, fluid bed coating or coating in supercritical fluids [51].
It should be mentioned that there is an innovative tool for pharmaceutical pre-
formulation of ODT tablets. This tool makes it possible to predict whether a disintegrating
excipient or a mixture of excipient powder + active substance is suitable for obtaining an
oral dispersible tablet by direct compression or not: the new model SeDeM-ODT [53].
The SeDeM-ODT model (based on the SeDeM expert system) indicates the ability of
a powder to be compressed, providing the Good Compressibility and oral dispersibility
Index (IGCB). This index is composed of six main factors which indicate whether a powder
mixture has the ability to be compressed by direct compression. Furthermore, it indicates
whether the tablets are suitable for formulation as oral dispersible tablets. Thus, the SeDeM-
ODT model facilitates the selection of excipients with the appropriate properties to produce
ODT tablets using direct compression technologies [53].
Figure 1 will detail several special features and advantages of ODT tablets [52,54].
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equipment allows the manufacture of tablets at low cost.
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Figure 2. isadvantages of ODT tablets.
Th response to drugs may be different among atients, due to inter-in ividual
variability, caused by both genet c and environmental fac ors. Accordingly, “patient-
specific” or “tailor-made” dosa e concepts could be an alternative to mass production in
the traditional pharmaceutical ind stry. In this a proach, 3D printi g has proven to be a
manufacturing technique with great potential, as it allows the creation of three-dimensional
objects, layer by layer, with total freedom of form and design. Thus, obtaining customized
pharmaceutical forms is one of the main objectives of 3D printing in the pharmaceutical
sector [55].
Paediatric patients are one of the population groups with the greatest need for per-
sonalized dosing adapted to their requirements (age, weight, pathological status, etc.).
However, most 3D printed drugs are solid oral formulations, which are not suitable for
this population group. Medicinal gummies developed through 3D printing (tailor-made
to the patient) could be a form of oral dosing suitable for paediatric patients, due to their
striking appearance and pleasant organoleptic characteristics [55].
New advances in obtaining medicines and medical devices, using 3D printing tech-
nology, have generated novel perspectives in the processes of obtaining these products. At
present; however, several issues are perceived that will need to be resolved as the perfection
and implementation of this technique progresses, in order to make it a common process of
obtaining medicines and medical devices.
5. Conclusions
The critical study suggests that excipients are often used at higher concentrations
than recommended in international paediatric guidelines, and with inappropriate labelling,
increasing the potential risks associated with the various excipients discussed [26].
Indeed, the pharmacokinetic and pharmacodynamic profiles of the child population
vary substantially, with paediatric safety profiles related to the age and development of
excipients often differing from those of adults [48]. The most toxic excipients in neonates
are known to be sodium benzoate, propylene glycol, methyl para hydroxybenzoate, propyl,
sodium saccharine, benzyl alcohol, benzalkonium chloride, polysorbate 80 and ethanol [56].
However, these excipients are used in formulations according to the study conducted.
European new-borns receive several potentially harmful pharmaceutical excipients:
parabens, polysorbate 80, propylene glycol, benzoates, sodium saccharine, sorbitol, ethanol
and benzalkonium chloride. According to the study conducted by Nellis and collabora-
tors [36], there are regional variations in the neonatal administration of these potentially
harmful excipients. This suggests the possibility of reducing exposure to parabens, polysor-
bate 80, propylene glycol and sodium saccharine by replacing it with products without
these excipients. However, a joint effort by the regulatory authorities on medicines, in
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particular the paediatric committees, will be necessary. Current therapeutic options for the
paediatric population justify further toxicokinetic and drug safety studies so that they are
tailored to the special needs of the paediatric population.
In general, there is little information regarding excipients in paediatrics. It is of the
utmost importance to develop new research related to the safety and toxicity of excipients
to reduce the prevalence of adverse effects in paediatric populations. Gallon formulators
can formulate safer, more stable and higher quality products. Furthermore, the possible
adverse effects of the active ingredients and the excipients used in the paediatric population
should be reconsidered—since excipients that are safe in adults—may have potentially
toxic effects in children.
Finally, the development of databases such as STEP is relevant and beneficial for the
development and use of drugs in paediatrics. Additionally, the SEEN project is relevant
both nationally and internationally, as it reveals the current status of excipients and takes
into account the frequency and quantity (in terms of medicines given to new-borns and
young children).
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Appendix A. Purposes of the STEP Database
More specifically, the purposes of the STEP database are [22] to:
1. Serve as a public base for evidence regarding the safety and toxicity of excipients in
order to allow the pharmaceutical industry, academics, pharmacists, physicians and
regulators to make informed decisions.
2. Improve prospects of identifying potential security issues in the early stages of the
development process when excipients are selected.
3. Help highlight any relationships between exposure and evidence of clinically signifi-
cant toxicity in the paediatric age group in general, or in paediatric subpopulations.
4. Identify possible differences in expression, types or patterns of toxicity in children
compared to adults. Provide a basis for assessing the need to generate new data for
paediatric medicines (e.g., bridge studies, juvenile toxicity studies, etc.), in order to
clarify what kind of new data, knowledge gaps or studies may be needed.
5. Support companies with their regulatory presentations with easily available informa-
tion.
6. Support and improve research activities by providing a platform to share unreleased
data and available data with corporate entities.
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Appendix B
Table A1. Most important characteristics of the excipients discussed in this paper (in alphabetical order).
Excipient Functions DAI * Recommendations Adverse Effects References











- Cross reaction with
sulfamides
[29,35]
Benzalkonium chloride Preservative NA






Benzyl alcohol Preservative 5 mg/kg
- Contraindicated in
children under 3 years
of age by immature
their metabolism
In new-borns and children under
3 years of age cause:
- Metabolic acidosis and
respiratory depression
- Intraventricular haemorrhage




Ethyl alcohol Solvent and preservative 6 mg/kg/dose (<6 years)
Paediatric formulations
should not exceed the
following limits of ethanol:
- In children over
12 years of age: less
than 10% (v/v)
- In children 6–12 years
old: less than 5% (v/v)
- In children under 6
years of age: less than
0.5 (v/v)
- Hypoglycaemia, acidosis and
hydroelectrolytic alterations
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Table A1. Cont.
Excipient Functions DAI * Recommendations Adverse Effects References
Glycerol Solvent, sweetener, viscosizerand preservative 10 g/dose
- Caution in paediatric
population
- Do not exceed the safe
daily dose (1.0–1.5 g/kg
body weight)
- Mucositis in the stomach








Symptoms of lactose intolerance:
severe abdominal pain, flatulence,
bloating or swelling and diarrhoea.
- Systemic symptoms such as
muscle and joint pain and
eczema





Parabens Preservative 10 mg/kg
- It is recommended to
avoid its use in
neonates
- Cross hypersensitivity





Phthalates Coating agents (plasticizers) NA
- Not recommended for
use in pregnant women
or children under
3 years of age
- Anomalies in the
development of the foetus:
cleft palate and skeletal
malformations. May lead to
stillbirth
[28]
Polyethylene glycol Solvent, suspensor andviscosity agent 10 mg/kg
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NA - Caution in new-borns
- Serious adverse effects:
deaths in low-weight
neonates who received
vitamin E preparations with
polysorbates.
- Polysorbate 80: increased
mortality in new-borns
[25,42]
Propyl gallate Antioxidant NA - Caution in new-borns
- In neonates it can cause
dermatitis, skin allergy and
methemoglobinemia
[29]
Propylene glycol Solvent, moisturizing andpreservative
- Neonates: 1 mg/kg
- Under 5 years: 50 mg/kg
- Adults: 500 mg/kg
- It is recommended to
avoid in children under
4 years of age because
of lack of metabolic
maturation
- CNS depression




Saccharine Sweetener 2.5 mg/kg
- It is recommended to
limit the daily dose in
pregnant women and
children
- Urticaria, itching and eczema
- Photosensitization
- GI disturbances: Nausea and
diarrhoea
[29,48]
Sorbitol Sweetener and diluent
- Children 0–2 years
5 mg/kg




- Not recommended for
use in patients with
hypoglycaemia
- Gastrointestinal disorders
- It can cause hepatic damage
with comma and even death
[28–30]
Starch Diluent and added NA
- Conservation in dry
environment
- Well tolerated by
children
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Sucralose Sweetener 15 mg/kg
- Caution in patients with
metabolic disorders
Alters the composition of the
digestive tract microbiome
- At high temperatures
chloropropanol may form
- May alter glucose, insulin
and GLP-1 *2 levels
[29]
Sucrose Sweetener NA
- Not recommended for
use in children with
type I diabetes
- Dental damage
- At very high doses on a daily
basis I could be carcinogenic
[29]




triphenylmethane, xanthines Colorants NA
- It is recommended not
to use them in
paediatric formulations










- Avoid use in vaccines as
a preservative due to its
side effects
- Hypersensitivity reactions
- Autism spectrum disorders
[28,29]
* ADI: Admissible Daily Intake; *2 GLP-1: Glucagon Like Peptide; NA: Not Available.
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Table A2. Examples of solid and semisolid medicines used in Spain for paediatric population: List of excipients and relevant characteristics of FF (Performed consultation of CIMA
database, September 2020).











Anhydrous sodium citrate, Colloidal
silica and Orange essence
Amoxicillin
- Powders are administered after
prior dissolution.
- They are little employees in the
paediatric population; present the
drawback that it is difficult to mask
the bad taste.
- Risk of accidental aspirations.
- They are usually used in master





200 mg/5 mL EFG Oral
Suspension Powder
Sucrose, Xanthan gum (E415),
Hydroxypropyl cellulose, Anhydrous
trisodium phosphate, Colloidal
anhydrous silica (E551), Aspartame







Calcium carbonate, Sodium hydrogen
carbonate, Citric acid anhydrous,
Anhydrous sodium citrate,
Aspartame (E-951), Sucrose, Mannitol
(E-421), Amorphous silica, Glycerol
die-stearate type 1, Croscarmellose
sodium, Sodium glycolate starch type





- Granules are more stable and fluid
than powders.
- The most used are effervescent
granules, which in the presence of
water react by releasing carbon
dioxide, which protects the stomach
and partly anesthetizes taste buds.
- They should be completely
dissolved prior to administration in
order to reduce bicarbonate intake.
- Children are often pleased by their
resemblance to certain refreshing
drinks.
[29,59]
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(E-951), Colloidal silica, Mannitol,
Talco, Magnesium stearate and Grape
essence
Paracetamol
As advantages of oral dispersible tablets,
the following stand out:
- They combine the advantages of
liquid forms and solid oral forms.
- An exact dose may be given
compared to liquids.
- They have a pleasant taste, thus
facilitating therapeutic compliance
in the paediatric population.
- No need to swallow the tablet or
drink water; dissolves rapidly in
saliva, being an appropriate choice
for patients with swallowing
problems, such as children or
geriatric patients.
- They are safe and effective and can
be bio-equivalent with respect to
conventional tablets.
- They have rapid absorption and,
therefore, a rapid introduction of
the therapeutic effect.
Disadvantages include:
- The lack of mechanical resistance
presented by traditional tablets.
- The possibility of physical
instability in excess moisture.
- ODTs require special conditioning





Ethyl cellulose, Precipitated silicon
dioxide, Hypromellose, Mannitol,
Aspartame (E-951), Croscarmellose
sodium, Magnesium stearate and
Lemon flavouring Ibuprofen
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Colloidal anhydrous silica, Solid
semi-synthetic glycerides Paracetamol
As advantages, the following stand out:
- Generally, they avoid gastric
intolerance problems.
- They are of interest when the
medicine is inactive orally, the
patient is unconscious or are
children who refuse to swallow the
medication.
- They avoid inactivation by the
effect of first liver step.
Disadvantages include:
- Reproducible behaviour can only be
obtained if absorbed into an area
two centimetres from the end of the
rectum.
- Absorption of the active substance
may be erratic.
- As it avoids the effect of first liver
step, it can increase the possibility
of poisoning.
- In certain cultures, it is a form that
is not well accepted socially.
[29,62]
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- It is a semi-soft transparent colloid,
with a large proportion of liquids.
- Low penetration power.
- Many incompatibilities with active
substances.
- It is easy to apply, pleasant and





CREAMS Example 1: Perme-Cure5% Cream
Butylhydroxytoluene
(E-321), Castor Oil, Deionized water,
Steareth-2, Ceteareth-2-Phosphate,
Sosa to the 20 %, Vitamin E acetate,




As advantages, the following stand out:
- Comfortable and easy application.
- Provide a controlled release of the
active substance.
- They act as emollients and







Liquid paraffin and White Vaseline Ciprofloxacin
- Ointments are forms of external use
intended to be administered by
gentle friction on a surface of the
body, to achieve a local action or
with the aim of penetrating the
drug through it.
- In many cases, the topical route is a
route of absorption comparable to
oral or other, so the dosage and
duration of treatment must be very
well specified. New-borns and
infants have a very increased
skin-to-weight ratio. Coupled with
the fact that at this age the skin is
very permeable, it makes them
especially vulnerable to toxic
frames by ointments.
[29,65]
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- This is a suspended ointment.
- They are used when you want to
locate the action of the active
substance to a specific area, as they














Sodium hydroxide, Stearyl alcohol,
Glycerol stearate, Cetyl alcohol,
Isopropyl palmitate, Mineral oil,
Myristyl lactate, Fragrance and Water
Hydrocortisone
- Emulsions are a dispersed system,
stabilized by the addition of an
adequate emulsifier, two immiscible
phases, where both the internal and
external phases are liquid.
- The emulsions enable fat-soluble
and water-soluble active
ingredients to come into contact
with the skin simultaneously,
encompassing each of them in the
phase of the emulsion for which
they have the greatest affinity.
- Patients or users of topical
application preparations often
prefer emulsion vehicles to those of
any kind.
[50,67]
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Table A3. Examples of liquid medicines used in paediatrics: List of excipients and relevant characteristics of Pharmaceutical Form.

















As advantages, the following stand
out:
- Release of the active
substance(s) much faster than
in solid forms.
- The dosages are correctly
expressed in milligrams,
micrograms and U/mL,
allowing them to be adapted
to the child’s weight.
- Easy and comfortable dosing,
as it is in volume (spoons,
drops, etc.)
- Less irritation effect if it is an
aggressive medicine, at the
gastric level, as it is
dampened by dilution.
- Solutions, suspensions or
emulsions are obtained,
depending on the size of the
particles of the internal phase.
As disadvantages they present:
[29,49,68–70]
Example 2: Paracetamol
Level 100 mg/mL Oral
Solution
Citric acid, Sodium hydroxide,
Sucrose, Propylene glycol,
Macrogol, Strawberry Essence,
Cochineal Red A (Ponceau 4R)




Intensol™ Oral Solution 5
mg/mL
* Do not use in children under
6 months of age




- Greater ease and possibility of
contamination than solid
pharmaceutical forms, which














hydroxide and Purified Water
Prednisolone
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section of the previous page
[73–75]Example 6: Flumil
20 mg/mL Oral Solution
Para-Hydroxybenzoate Methyl













Phosphate, Citric Acid (E-330),
Methyl Hydroxybenzoate, Lime
Essential Oil, Propylene glycol












Gum, 70% Sorbitol Solution,
Sucrose, Mango flavour and
Purified Water
Paracetamol
As advantages, the following stand
out:
- Suspensions are the ideal




- The fact that the active
substance is insoluble, allows
an extension of the time of
action in the body.
- It is easier to mask the taste
than in syrups and elixirs
(more pleasant for children).
- Good relative bioavailability.
[76,77]
Example 2: Junior Parapaed






saccharine (E954), xanthan gum,
cherry flavour, sodium benzoate,
Citric acid monohydrate and
purified water
Paracetamol
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- Difficulty removing the
viscosity of the vehicle.
- Less stability than solid
shapes, solutions and
emulsions.
- The use of very fine particle
size causes the formation of
sediments that are very
difficult to re-suspend.
It is important to shake the suspension
for at least 10 s before use
[78,79]
Example 4: Paediatric
Algidrin 20 mg/mL Oral
Suspension
* Do not give to children under







Forest Fruit Aroma, Allura AC











Septrin 8 mg/40 mg/mL
Oral Suspension
* Suitable for infants from








Glycol E-1520, Sodium Citrates











section of the previous page
[80]
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Pharmaceutical Form Excipients API Pharmaceutical FormCharacteristics References
LIQUID PREPARATIONS ELIXIRS
Example 1: Paracetamol
Elixir Pediátrico 120 mg/
5 mL








- Hydro alcoholic solution
sweetened with low sugar.
- It has high alcohol content,
which will have to be
considered at certain ages, as
it can create addition or




Example 2: Lanoxin Elixir







flavour and Purified Water
Digoxin
SYRUPS











- Syrups are liquid solutions
with sweetening, flavouring
and viscosizing properties.
They are almost saturated
aqueous solutions of sucrose
(64%).
They have the following drawbacks:










Peach flavour and Purified
Water
Loratadine
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* Not suitable for children
















Mucosan 3 mg/mL Syrup
Hydroxyethyl cellulose,
Sucralose, Benzoic Acid
(E-210), Wild Berry Aroma,










15 mg/mL Oral drops in
Solution
* Not recommended for use


















- Oral liquid medicinal
products may be placed on
the market in the form of
drops for children of different
ages.




As disadvantages, the following
stand out: the variation of the
droplet size and errors in the count,
which would result in an incorrect
dosage. This can cause serious




10 mg/mL Oral Drops in
Solution
* Do not use in children under
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LIQUIDPREPARA-TIONS ORAL DROPS IN
SOLUTION
Example 3: Paediatric







Characteristics (Oral Drops in
Solution)” section of the
previous page
[91–93]
Example 4: Fluor Lacer
1.4 mg/mL Oral Drops














Oral Drops in Solution
* Recommended for children
over 2 years old
Propylene glycol,





















LIQUID PREPARATIONS ORAL DROPS
INSUSPENSION
Example 1: Zamene
22.75 mg/mL Oral Drops in
Suspension
* Special interest in
paediatrics.
Not recommended in







80, Acetic Acid and Purified
Water
Deflazacort They have the same characteristics
as oral drops in solution
[94,95]
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Pharmaceutical Form Excipients API Pharmaceutical FormCharacteristics References
Example 2: Dezacor
22.75 mg/mL Oral Drops in
Suspension
* Special interest in
paediatrics.
Not recommended in















Example 1: Atropine BP
1.0% (w/v)/Vistatropin 1.0%
(w/v) Eye drops in solution
Benzalkonium chloride in
solution and purified water Atropine sulphate - Sterile solutions aimed atexercising their action in the
conjunctiva.
- May cause systemic side
effects, especially observed










Acid, Sodium Chloride and
Water for Injections
Norfloxacin
LIQUID PREPARATIONS NASAL DROPS
Example 1: Rhinovin®
Children’s 0.5 mg/mL
Nasal Drops in Solution
* Do not use in children under








Chloride and Purified Water
Xylometazoline
hydrochloride
- Aqueous solutions of
medicinal substances that are
instilled through the nose and
act on the nasal mucosa.
- Oils are contraindicated in
their formulation, because the
ciliary function has to be
maintained.
- It can be an excellent route of
systemic administration, in
addition to use as a topical
route (there are promising
studies with insulin and other
substances).
[29,68,98,99]
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Example 2: Utabon
Children 0.25 mg/mL Nasal
Drops in Solution
* Do not use in children under











Example 1: Otic cetraxal
3 mg/mL Otic drops en
Solución









Ciprofloxacin - Liquid preparations to apply
to the middle and outer ear.
- The active substances are
usually antiseptics, local
anaesthetics and antibiotics.
Excipients have to be suitable to
achieve a pH of 5–6.
[29,100,101]
Example 2: Otix Otic Drops
in Solution
* Do not administer in















LIQUID PREPARATIONS OTIC DROPS
Example 3: Ciproxin Simple
3 mg/mL Otic Drops in
Solution
* Not recommended for











Characteristics (Otic Drops)” section

















- The intravenous line is the
one of choice in new-borns
and in emergencies. It
achieves a quick effect and are
easy to dos.
- Risk of infection and can be
painful at times and cause
difficult-to-resolve injuries.
[29,103]
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Table A4. Examples of FDA-registered drugs used in paediatrics (FDA and DAILYMED database consultation October 2020).





Disodium edetate, fructose (200 mg per mL),
glycerine, dl-lactic acid, methylparaben,
propylene glycol, propylparaben, sodium
hydroxide, sucrose (400 mg per mL), and purified
water. The Oral solution is flavoured with natural
orange cream and other natural flavours
Aripiprazole 6 to 18 years [104]
Demerol Solution Oral Benzoic acid, flavour, liquid glucose, purifiedwater, saccharin sodium Meperidine hydrochloride Adult and paediatric patients [105]
Diazepam Oral Solution
(Lannett Company)
Polyethylene glycol, propylene glycol,
non-crystallizing sorbitol solution, sodium citrate
anhydrous, bitterness modifier flavour, anhydrous
citric acid, peppermint flavour, mint flavour,
FD&C Network No. 40 aluminium lake, D&C
Yellow No. 10 aluminium lake and purified water
Diazepam (5 mg/5 mL) Children from 6 months [106]
ORAL
SUSPENSIONS
Adzenys ER (Extend release)
Purified water, sorbitol, propylene glycol, xanthan
gum, natural orange flavour, methacrylic acid and
methyl methacrylate copolymer, sodium
polystyrene sulfonate, vegetable oil, triethyl
citrate, methylparaben, citric acid, sucralose,
propylparaben, orange colour (FD&C Yellow No.
6), and polyethylene glycol
Amphetamine 6 to 17 years [107]
Children’s Tylenol® Cold +
Cough + Sore Throat Oral
Suspension
Anhydrous citric acid, D&C network No. 33,
FD&C network No. 40, flavours, glycerine,
microcrystalline cellulose and sodium
carboxymethyl cellulose, purified water, sodium





4 to 11 years [108]
ORAL SUSPENSIONS Dyanavel XR (Extend release)
Anhydrous citric acid, bubble-gum flavour,
glycerine, methylparaben, modified food starch,
polysorbate 80, povidone, polyvinyl acetate,
propylparaben, sodium lauryl sulphate, sodium
polystyrene sulfonate, sucralose, triacetin and
xanthan gum
Amphetamine Children from 6 years [109]
SYRUPS Midazolam hydrochloridesyrup
Anhydrous Citric Acid, D&C Network No. 33,
edetate disodium, glycerine, sodium benzoate,
sorbitol, Water, Hydrochloric Acid, Sodium
Citrate
Midazolam hydrochloride Children from 6 months [110]
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Benzalkonium chloride, boric acid, edetate
disodium, acetic acid, sodium acetate, sodium
chloride, sodium hydroxide, tyloxapol, water,
hydrochloric acid, hydroxyethyl cellulose










Benzalkonium chloride 0.01%, glycerine, purified
water. may contain hydrochloric acid and/or
sodium




Children from 3 years.









Benzalkonium chloride, glycerine, polyethylene
glycol, potassium phosphate monobasic, purified
water,





ORAL DROPS BIO-G-TUSS PAEDIATRICDROPS (solution)















Acesulfame potassium, ammonium glycyrrhizin,
aspartame, carnauba wax, croscarmellose sodium,
hypromellose, magnesium stearate, mannitol,
natural and artificial flavours, silicon dioxide,
sodium lauryl sulphate, soybean oil, succinic acid
Ibuprofen 100 mg 2 to 11 years [115]
Acetaminophen Children’s
Citric acid, crospovidone, D&C network No. 27
aluminium lake, D&C network No. 30 aluminium
lake, dextrates hydrated, ethyl cellulose, flavours,
magnesium stearate, mannitol, polyethylene,
stearic acid, sucralose
Acetaminophen 80 mg 2 to 6 years [116]
TABLETS
Diazepam Tablet Anhydrous lactose, magnesium stearate, cellulosemicrocrystalline, FD&C blue n. 1 Diazepam 10 mg Children from 6 months [117]
Dexamethasone 1.5 mg tablet Lactose monohydrate, magnesium stearate,maltodextrin, corn starch, sucrose Dexamethasone 1.5 mg It depends on the pathology [118]
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Table A5. Liquid formulations for paediatric use in Research Articles.
Formula Pharmaceutical Form Excipients Active Principle (Dose) Age Stability(Stability in Use) References
Organic solvent-based formulation of
lorazepam (Oral Solution) Oral solution
PEG 400 (10% v/v), Propylene glycol (3% m/v),
Glycerol (87% v/v) and Orange essence (0.1%) Lorazepam (1 mg/mL)
Children 1 month to
12 years old
12 months at 4 ◦C
(Stability in use: 4 weeks) [119]
Oral solution of amlodipine besylate for
children Oral solution
Sucrose jarabe (32% m/v), Methylparaben (solution





12 months at 4 ◦C
(Stability in use: 18 weeks) [120]
Oral tizanidine hydrochloride,
Formulation for hospital use Oral solution
CMC (carboxymethyl cellulose) (0.5%), Potassic
sorbate (0.15%), Sucralose (0.10%), Citric acid and
Purified water
Tizanidine Hydrochloride
(1 g/mL) Paediatric Population
70 days at 15–30 ◦C, 2–8 ◦C
and 40 ◦C [121]
Paediatric oral formulation of clonidine
hydrochloride Oral solution
Sucrose syrup (20% v/v), Raspberry essence
(0.05%), Methyl paraben solution 15% (1% m/v),
Citric acid monohydrate (1% m/v), Disodium
hydrogen phosphate (1.8% m/v) and
Purified water
Clonidine HCL
(50 µg/mL) Paediatric Population




Oral liquid formulation of clonidine
hydrochloride for paediatric patients Oral solution






90 days at 5 ◦C (cooling)
(Stability in use: 42 days at
5 ◦C)
[123]
Paediatric oral formulations of sodium
dichloroacetate Oral solution
Vehicle Mascagni (% w/v): Sucralose (0.02%),
Hydroxyethyl cellulose (0.2%), Citric acid (0.09%),
Sodium citrate (0.09%) and Potassium sorbate
(0.18%)
Sodium dichloroacetate
(DCA) (9.5% w/v) Paediatric Patients
3 months at 4 ◦C and 25 ◦C
(Stability in use: 1 month
to 4 ◦C)
[124]




Solution I: Buffer carbonate-bicarbonate (pH)
(10 mL)
Excipient for syrup (cps 100 mL) (ACOFARMA):
sucrose, water, sorbitol, glycerine, aroma, citric
acid, methyl paraben, potassium sorbate, sodium
phosphate and colorant.
Solution II: Buffer carbonate-bicarbonate (pH)
(10 mL)
-Excipient for syrup—without sugars (cps 100 mL)
(ACOFARMA): sodium saccharine, xanthan gum,
water, sorbitol, glycerine, aroma, citric acid,
sodium citrate, methyl paraben, propyl paraben,
potassium sorbate, sodium phosphate and
colorant.
Furosemide (2 mg/mL) Paediatrics 60 days at 4 and 25 ◦C [125]
Formulation comprising acetaminophen,
especially for paediatrics (PATENT) Oral solution (nano-emulsion)
NF glyceryl mono linoleate (5–30%, preferably
8-26% w/v), PEG-35 castor oil (30–60%, preferably
39–46% w/v), NF diethylene glycol mono ethyl
ether (20–45%, preferably 24–40% w/v) and Water
Paracetamol (5–18% w/v) Paediatrics NA [126]
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Paediatric formulations of
ursodeoxycholic acid from oral
administration
Oral suspension Glycerol (20%), Methyl cellulose 1000 (1% v/v) andPurified water
Ursodeoxycholic acid
(UDCA) (1.5 mg/mL) Paediatric Population
30 days at 25 ◦C or in
fridge [127]
Oral paediatric formulation of
hydrochlorothiazide Oral suspension
Glycerol (20%), Methyl cellulose 1000 (1% v/v),





3 weeks at 5 ◦C and
protected from light [128]
Oral suspension of clindamycin HCL
with ion exchange resin for paediatric
use
Oral suspension
Glycerine (30% w/v), Sucralose (3%), Aroma of
maple syrup (7%), Grape aroma (10%),
Cremophor RH 40 (15%), Xanthan gum (0.2%) and




Paediatric Population 1 month at 25 ◦C [129,130]
Isoniazid suspension formulated with
cationic resin for paediatric use Oral suspension
Sorbitol solution 70% USP (4.9 mL/ 5 mL), USP
monohydrate citric acid (50 mg/5 mL) and USP
potassic sorbate (5 mg/5 mL)
Isoniazid resin/Kyron
T-134
100 mg/5 mL/200 mg/
5 mL
Paediatric Population




Paediatric xylometazoline nasal spray
formulation Nasal Spray
Sodium colatum (105 mg/10 mL), PEG 400
(1.35 mL/10 mL), Sodium carboxy methyl
cellulose (10 mg/10 mL), Glycerine
(0.15 mL/10 mL), Methyl paraben (3.3 mg/10 mL),
Sodium chloride and Purified water (cps 10 mL)
Xylometazoline HCl
(5 mg/10 mL) Paediatric Population 12 months at 25
◦C [132]
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